SBIR Phase I: Improved COVID-19 Testing by Rapid Sample Purification

小型企业创新研究(SBIR)第一阶段项目的更广泛影响/商业潜力是提高了冠状病毒检测的可靠性。拟议的项目将开发一种组织纯化技术，从患者样本中提取(纯化)病毒。更纯净的样本(冠状病毒更多，混杂物质更少)有望改善来自病毒的信号，减少来自非病毒材料的信号，因此预计将提高检测的可靠性(更少的假阳性和假阴性)。这可能会影响大流行的社会距离。这个小型企业创新研究(SBIR)第一阶段项目是一个提取纯化样本的系统，用于冠状病毒检测，用于下游检测，如基于聚合酶链式反应的分析。该系统是一种新颖的纯化技术，它使用生物(抗体)和其他物理手段快速、可靠地从人类样本中提取目标微生物(这里是COVID病毒)。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is an improved reliability for coronavirus detection. The proposed project will develop a tissue purification technology to extract (purify) virus from patient samples. Purer samples (more coronavirus, less confounding materials) is anticipated to improve signal from virus and reduce signal from non-virus materials, and is therefore anticipated to improve the reliability of testing (fewer false positives and false negatives). This can potentially impact the social distancing of the pandemic. This Small Business Innovation Research (SBIR) Phase I project of a system to extract purified samples for coronavirus testing for downstream testing, such as PCR-based analysis. The system is a novel purification technology that uses biological (antibodies) and other physical to quickly and reliably extract target microorganisms (here COVID viruses) from human samples.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.